Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir

Treatment of HCV genotype 1b (GT1b)-infected Japanese patients with paritaprevir (NS3/4A inhibitor boosted with ritonavir) and ombitasvir (NS5A inhibitor) in studies M12-536 and GIFT-I demonstrated high sustained virologic response (SVR) rates. The virologic failure rate was 3% (13/436) across the t...

Descripción completa

Detalles Bibliográficos
Autores principales: Krishnan, Preethi, Schnell, Gretja, Tripathi, Rakesh, Beyer, Jill, Reisch, Thomas, Zhang, Xinyan, Setze, Carolyn, Rodrigues, Lino, Burroughs, Margaret, Redman, Rebecca, Chayama, Kazuaki, Kumada, Hiromitsu, Collins, Christine, Pilot-Matias, Tami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2016
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750684/
https://www.ncbi.nlm.nih.gov/pubmed/26643326
http://dx.doi.org/10.1128/AAC.02606-15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750684/
https://www.ncbi.nlm.nih.gov/pubmed/26643326
http://dx.doi.org/10.1128/AAC.02606-15

Ejemplares similares